Samsung Bioepis Confident Eylea And Lucentis Biosimilars Can Coexist
Korea-Based Firm’s Phase III Aflibercept Data Expected This Year
In an exclusive interview, Samsung Bioepis’ head of clinical research, Il Sun Hong, tells Generics Bulletin how the company managed to put itself at the head of the pack in the chase for biosimilar Eylea (aflibercept); and how the biosimilar can coexist with biosimilars to Lucentis (ranibizumab), which may debut later this year.
